| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage immuno-oncology company pioneering novel therapies to enhance cancer treatment. Focused on leveraging the immune system to combat malignancies, ALX Oncology's lead candidate, ALX148, is a CD47 blocker in Phase 1b/2 trials targeting hematologic cancers (e.g., AML, MDS) and solid tumors (e.g., HER2+ gastric, breast, and head/neck cancers). The company’s pipeline also includes ALTA-002, a SIRPa TRAAC designed to activate innate and adaptive immunity. Strategic collaborations with Merck, Zymeworks, and Tallac Therapeutics bolster its clinical development, while partnerships with Selexis SA and Crystal Bioscience enhance manufacturing capabilities. Headquartered in South San Francisco, ALX Oncology operates in the high-growth biotechnology sector, addressing unmet needs in oncology with a focus on combination therapies. With no approved products yet, its valuation hinges on clinical milestones and partnerships, positioning it as a high-risk, high-reward player in immuno-oncology.
ALX Oncology presents a speculative investment opportunity with significant upside tied to clinical success but carries substantial risk due to its pre-revenue status and cash burn. The company’s lead asset, ALX148, targets CD47—a promising but competitive pathway in immuno-oncology—with early data showing potential in combination therapies. Partnerships with Merck and Zymeworks validate its approach but also expose it to competition from larger peers (e.g., Gilead, Bristol-Myers). Negative EPS (-$2.58) and operating cash flow (-$121.9M in FY2023) highlight reliance on capital markets for funding. Investors should monitor Phase 2 readouts and partnership milestones, as positive data could drive upside, while setbacks may exacerbate liquidity concerns. The stock’s high beta (1.21) reflects volatility typical of clinical-stage biotechs.
ALX Oncology’s competitive edge lies in its focus on CD47 inhibition, a mechanism gaining traction for its role in immune evasion by tumors. ALX148 differentiates via engineered Fc inactivation, aiming to reduce toxicity (e.g., anemia) seen with rival CD47 blockers. However, the space is crowded: Gilead’s magrolimab (acquired via Forty Seven) leads in late-stage trials, while Trillium Therapeutics (acquired by Pfizer) and Surface Oncology also advance CD47 candidates. ALX’s collaborations with Merck (Keytruda combinations) and Zymeworks (HER2 bispecifics) provide validation but hinge on competing effectively against established checkpoint inhibitors. The company’s capital constraints ($17.6M cash vs. $134.8M net loss in FY2023) limit R&D flexibility compared to deep-pocketed rivals. Its preclinical SIRPa TRAAC (ALTA-002) could offer differentiation but remains unproven. Success depends on demonstrating superior safety/efficacy in niche indications (e.g., HER2+ cancers) where larger players may not prioritize.